Lupus Foundation of America Statement on Results for Clinical Study
of CellCept Released by Aspreva Pharmaceutical Company
Statement by Sandra C. Raymond, President & CEO of the LupusFoundation of America, Inc. WASHINGTON, June 27, 2007 /PRNewswire-USNewswire/ -- The LupusFoundation of America, Inc. and more than 1.5 million Americanswith lupus have been awaiting the preliminary findings of the PhaseIII clinical trials for CellCept(R), a potential treatment forlupus kidney disease being tested by Aspreva...
Genetics Journal Thimerosal/Autism Study the 'Best Science Drug
Company Money Can Buy'
Critique of Industry-Funded Immune Globulin Study Uncovers SampleManipulation, Design Flaws NIXA, Mo., June 26, 2007 /PRNewswire-USNewswire/ -- An analysisreleased today critically examined a recent industry-sponsoredstudy ruling out a link between autism and Rh immune globulin(RhIg) injections, some of which contained the mercury-basedpreservative thimerosal. Besides extensive design fla...
Phosphagenics Announces Positive Proof of Concept Results from
Studies Utilizing Company's Dermal Drug Delivery Technology
MELBOURNE, Australia, June 25, 2007 /PRNewswire-FirstCall/ --Phosphagenics Limited (AIM: PSG) announced today positive resultsfrom pre-clinical studies of its TPM-02 dermal drug deliverytechnology formulated with retinoic acid, a leading topicaltreatment for severe acne and an active ingredient used inanti-aging cosmetics. The proof of concept studies showed a three-fold increase i...
FDA Announces Results of Investigation Into Illegal Promotion of
OxyContin by The Purdue Frederick Company, Inc.
Company Misrepresented Prescription PainReliever to Health Care Professionals ROCKVILLE, Md., May 10, 2007-The U.S. Food and DrugAdministration's (FDA) Office of Criminal Investigations (OCI)announced today that The Purdue Frederick
Company, Inc. has agreedto pay more than $700 million to resolve criminal charges and civilliabilities in connection with...
Catalyst Pharmaceutical Partners, Inc. Announces Top-Line Results
of Its Bioequivalence Study of CPP-109 (Vigabatrin), the Company's
Investigational Drug to Treat Cocaine and Methamphetamine Addiction
CORAL GABLES, Fla., May 09, 2007 /PRNewswire-FirstCall/ --Catalyst Pharmaceutical Partners, Inc. announced today positiveinitial, top-line results from a bioequivalence study demonstratingthat CPP-109 (Catalyst's Vigabatrin Tablets) is bioavailable andbioequivalent to Sabril Tablets, the version of vigabatrin marketedin Europe by Sanofi Aventis. These data potentially provide a basisfor...
Peregrine Pharmaceuticals Highlights Significant Advances in the
Company's Clinical and Preclinical Cancer Programs Presented This
Week at the AACR Annual Meeting
- New Study Demonstrated the Clinical Potential of Peregrine'sUnique Selective Anti-VEGF Antibodies, Which Were as Effective asAvastin(R) in Animal Cancer Models TUSTIN, Calif., April 20, 2007 /PRNewswire-FirstCall/ --Peregrine Pharmaceuticals, Inc. , a clinical stagebiopharmaceutical
company developing targeted monoclonal antibodiesfor the treatment of cancer and hepatitis C virus infect...
MIV Therapeutics Announces Pivotal Test Results Further Validating
Company Stent Coatings Meet Critical FDA Fatigue Guidelines
ATLANTA--(BUSINESS WIRE)--Apr 5, 2007 - MIV Therapeutics Inc.(OTCBB:MIVT) (FWB:MIV), a leading developer of next-generationbiocompatible coatings and advanced drug delivery systems forcardiovascular stents and other implantable medical devices, todayannounced that a recent
Company sponsored bench test confirmed thatmerging Biosync Scientific's certified bare metal stent platform,which MIVT...